The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: 0.05 (8.33%)
Spread: 0.10 (16.667%)
Open: 0.60
High: 0.00
Low: 0.00
Prev. Close: 0.60
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Provexis plc

6 Jun 2005 17:05

AIM06 June 2005 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Provexis plc COMPANY ADDRESS:10 Williams House Manchester Science Park Lloyd Street North Greater Manchester COMPANY POSTCODE:M15 6SE COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS:Nutraceutical company which develops scientifically proven, proprietary, functional foods, supplements andmedical foods DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):249,628,324 ordinary shares of 1p each comprising: 33,218,388 shares (Capital reorganisation of Existing Shares) 67,424,000 shares (Placing) 111,658,555 shares (Vendor consideration) 37,327,381 shares (Loans conversion) CAPITAL TO BE RAISED ON ADMISSION:£3.8 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Dawson Buck (Non-executive Chairman) Neville Bain (Non-executive Deputy Chairman) Stephen Franklin (Chief Executive) Stephen Moon (Commercial Director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUEDSHARE CAPITAL BEFORE ADMISSION: Number of ordinary Percentage of issued shares share capitalRising Stars Growth Fund 58,959,444 23.62Progeny BioVentures Limited 31,969,179 12.81ANGLE Technology Limited 29,926,464 11.99North West Equity Fund 13,514,990 5.41Rowett Research Services Limited 13,167,873 5.28 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (G) OFTHE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:31 March EXPECTED ADMISSION DATE:23 June 2005 NAME AND ADDRESS OF NOMINATED ADVISER:Arbuthnot Securities Limited Arbuthnot House 20 Ropemaker Street London EC2Y 9AR NAME AND ADDRESS OF BROKER:Arbuthnot Securities Limited Arbuthnot House 20 Ropemaker Street London EC2Y 9AR DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH ASTATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITSSECURITIES:Arbuthnot Securities Limited Arbuthnot House 20 Ropemaker Street London EC2Y 9AR The Admission document contains full details about the applicant and the admission of itssecurities. DATE OF NOTIFICATION:6 June 2005 NEW/ UPDATE (see note):New QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:N/ATHE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED: THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED: CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORYREQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET: AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THELAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE: DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILSOF ITS INVESTMENT STRATEGY: A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURREDSINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED: A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILIABLE TOIT OF ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION: DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES: A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES: A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES: INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC: A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE AFINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION. THE ACCOUNTS MUST BE PREPARED ACCORDING TO UKOR US GAAP OR INTERNATIONAL ACCOUNTING STANDARDS. THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TRESURY. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.